HomeAbout UsOur Expertise

EXPERTISEWorldwide recognised and published experience

Papers

Our staff and collaborators have authored 300+ papers over many years.

Patents

  • Method for determining exposure to mycobacteria – Publication No. WO2012/131394 (A1)
  • Method for determining the presence or absence of a biomarker – Publication No. WO2012/153111 (A1)
  • Kit and method – Patent No. 1514411.6 – Filed 2015
  • Compositions and Methods – Publication No. WO2017/025758 (A1)
  • Compositions and Methods – Publication No. WO2017/025757 (A1)
  • Compositions and Methods – Publication No. WO2010/086667 (A2)
  • Compositions and Methods – Publication No. WO2009/081211 (A2)
  • Method and kit for detection of mycobacterium – Publication No. WO2016/024118 (A1)
  • A microbial sensor – Patent No. 1101021.2 – Filed 2013

CHEMICAL SYNTHESISMycolic Acids

Capable of producing pure fully synthetic mycolic acids and their sugar esters.

Using established practices and published methods, in dedicated synthetic facilities. Whilst also providing end material analysis via NMR, MS and other specialist techniques.

Including but not limited to:

  • Trehalose mono and di mycolates
  • Arabinose mono, di and glucose mycolates
  • Glucose mono mycolates
  • Glycerol mycolates
  • Wax ester mono and dimycolates

DIAGNOSTICSMycobacteria ELISA

Experience in developing ELISAs for various mycobacterial infections.

By using novel lipid antigens we have been able to develop assays for specific mycobacterial diseases.

Expertise in research and development of assays for:

  • M. tuberculosis
  • M. bovis
  • M. paratuberculosis
  • M. ulcerans
  • M. abscessus

CHEMICAL SYNTHESISMycobacterium Cell Wall Compounds

Alongside our core technology we are also capable of producing many other compounds found in mycobacteria.

Including:

  • Fatty acids
  • Phospholipids
  • Glycolipids

DIAGNOSITCSPoint of Care Devices

Diagnostig was spun out of Bangor University as a Point of Care diagnostics company, and our class 2 biological facility allows us to develop these capabilities based on our ELISA assays.